Proactive Investors - Run By Investors For Investors

Bard1 Life Sciences is one of the ASX’s most active top performers today

The company is developing a non-invasive diagnostic test for ovarian cancer.
someone working in a science lab
There is clear opportunity in the growing US$7.2 billion ovarian cancer market

Bard1 Life Sciences Ltd (ASX:BD1) is one of the most actively traded stocks on the ASX today with over 88 million shares changing hands around 2.00pm AEST.

Furthermore, the heavy volume in the stock has pushed shares up 22.7%.

Only one other stock has had more shares traded today and that is Blackham Resources Ltd (ASX:BLK) with 280 million shares traded, up 41.5%.

READ: Blackham Resources surges 40% as output increases and costs fall

BARD1 is a biotechnology company developing non-invasive cancer diagnostics.

Earlier this week, the company received additional positive results from the application of its BARD1-Ovarian test.

Testing confirmed high accuracy for detection of ovarian cancer with 89% sensitivity and 82% specificity.

Commercialising the company’s diagnostic test

BARD1 is currently in discussions with a number of contract laboratory organisations to transfer its work to date to a commercial platform.

This will enable the BARD1 tests to be performed by most hospital and independent clinical laboratories around the world.

Opportunity the ovarian cancer market presents

The global ovarian cancer diagnostics market was valued at US$7.2 billion in 2013.

It was expected to grow at 7.2% annually to reach US$11.8 billion by 2020.

There is a clear unmet clinical need for non-invasive, accurate and affordable diagnostic tests for the early detection and monitoring of ovarian cancer.

View full BD1 profile View Profile

Bard1 Life Sciences Ltd Timeline

Related Articles

Long-term fundamentals remain firmly in the seafood specialist's favour
Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use